JP5426850B2 - Influenza vaccine adjuvant - Google Patents
Influenza vaccine adjuvant Download PDFInfo
- Publication number
- JP5426850B2 JP5426850B2 JP2008210484A JP2008210484A JP5426850B2 JP 5426850 B2 JP5426850 B2 JP 5426850B2 JP 2008210484 A JP2008210484 A JP 2008210484A JP 2008210484 A JP2008210484 A JP 2008210484A JP 5426850 B2 JP5426850 B2 JP 5426850B2
- Authority
- JP
- Japan
- Prior art keywords
- strain
- positive
- lactic acid
- influenza vaccine
- adjuvant
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 229960003971 influenza vaccine Drugs 0.000 title claims description 24
- 239000012646 vaccine adjuvant Substances 0.000 title claims description 4
- 240000006024 Lactobacillus plantarum Species 0.000 claims description 15
- 235000013965 Lactobacillus plantarum Nutrition 0.000 claims description 11
- 229940072205 lactobacillus plantarum Drugs 0.000 claims description 11
- 239000004480 active ingredient Substances 0.000 claims description 6
- JVTAAEKCZFNVCJ-UHFFFAOYSA-N lactic acid Chemical compound CC(O)C(O)=O JVTAAEKCZFNVCJ-UHFFFAOYSA-N 0.000 description 47
- 235000014655 lactic acid Nutrition 0.000 description 23
- 239000004310 lactic acid Substances 0.000 description 23
- 241000894006 Bacteria Species 0.000 description 18
- 239000002671 adjuvant Substances 0.000 description 17
- 241000712461 unidentified influenza virus Species 0.000 description 11
- 230000000694 effects Effects 0.000 description 7
- 229960005486 vaccine Drugs 0.000 description 7
- 241000699670 Mus sp. Species 0.000 description 6
- NHBKXEKEPDILRR-UHFFFAOYSA-N 2,3-bis(butanoylsulfanyl)propyl butanoate Chemical compound CCCC(=O)OCC(SC(=O)CCC)CSC(=O)CCC NHBKXEKEPDILRR-UHFFFAOYSA-N 0.000 description 4
- ZHNUHDYFZUAESO-UHFFFAOYSA-N Formamide Chemical compound NC=O ZHNUHDYFZUAESO-UHFFFAOYSA-N 0.000 description 4
- 235000008429 bread Nutrition 0.000 description 4
- 235000013305 food Nutrition 0.000 description 4
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 3
- SRBFZHDQGSBBOR-UHFFFAOYSA-N beta-D-Pyranose-Lyxose Natural products OC1COC(O)C(O)C1O SRBFZHDQGSBBOR-UHFFFAOYSA-N 0.000 description 3
- 229920002261 Corn starch Polymers 0.000 description 2
- SRBFZHDQGSBBOR-SOOFDHNKSA-N D-ribopyranose Chemical compound O[C@@H]1COC(O)[C@H](O)[C@@H]1O SRBFZHDQGSBBOR-SOOFDHNKSA-N 0.000 description 2
- 238000002965 ELISA Methods 0.000 description 2
- 229930006000 Sucrose Natural products 0.000 description 2
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 2
- 239000000654 additive Substances 0.000 description 2
- 239000008120 corn starch Substances 0.000 description 2
- YPHMISFOHDHNIV-FSZOTQKASA-N cycloheximide Chemical compound C1[C@@H](C)C[C@H](C)C(=O)[C@@H]1[C@H](O)CC1CC(=O)NC(=O)C1 YPHMISFOHDHNIV-FSZOTQKASA-N 0.000 description 2
- 230000002708 enhancing effect Effects 0.000 description 2
- 239000012530 fluid Substances 0.000 description 2
- 210000003405 ileum Anatomy 0.000 description 2
- 210000002429 large intestine Anatomy 0.000 description 2
- 239000000463 material Substances 0.000 description 2
- 239000000203 mixture Substances 0.000 description 2
- 239000000843 powder Substances 0.000 description 2
- 210000000813 small intestine Anatomy 0.000 description 2
- 239000005720 sucrose Substances 0.000 description 2
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 2
- HDTRYLNUVZCQOY-UHFFFAOYSA-N α-D-glucopyranosyl-α-D-glucopyranoside Natural products OC1C(O)C(O)C(CO)OC1OC1C(O)C(O)C(O)C(CO)O1 HDTRYLNUVZCQOY-UHFFFAOYSA-N 0.000 description 1
- XUCIJNAGGSZNQT-JHSLDZJXSA-N (R)-amygdalin Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1OC[C@@H]1[C@@H](O)[C@H](O)[C@@H](O)[C@H](O[C@@H](C#N)C=2C=CC=CC=2)O1 XUCIJNAGGSZNQT-JHSLDZJXSA-N 0.000 description 1
- OWEGMIWEEQEYGQ-UHFFFAOYSA-N 100676-05-9 Natural products OC1C(O)C(O)C(CO)OC1OCC1C(O)C(O)C(O)C(OC2C(OC(O)C(O)C2O)CO)O1 OWEGMIWEEQEYGQ-UHFFFAOYSA-N 0.000 description 1
- PLXMOAALOJOTIY-FPTXNFDTSA-N Aesculin Natural products OC[C@@H]1[C@@H](O)[C@H](O)[C@@H](O)[C@H](O)[C@H]1Oc2cc3C=CC(=O)Oc3cc2O PLXMOAALOJOTIY-FPTXNFDTSA-N 0.000 description 1
- 241000304886 Bacilli Species 0.000 description 1
- 102000016938 Catalase Human genes 0.000 description 1
- 108010053835 Catalase Proteins 0.000 description 1
- 229920002101 Chitin Polymers 0.000 description 1
- 102000009016 Cholera Toxin Human genes 0.000 description 1
- 108010049048 Cholera Toxin Proteins 0.000 description 1
- WNBCMONIPIJTSB-BGNCJLHMSA-N Cichoriin Natural products O([C@H]1[C@H](O)[C@@H](O)[C@@H](O)[C@@H](CO)O1)c1c(O)cc2c(OC(=O)C=C2)c1 WNBCMONIPIJTSB-BGNCJLHMSA-N 0.000 description 1
- GUBGYTABKSRVRQ-CUHNMECISA-N D-Cellobiose Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)OC(O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-CUHNMECISA-N 0.000 description 1
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 1
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 1
- RGHNJXZEOKUKBD-UHFFFAOYSA-N D-gluconic acid Natural products OCC(O)C(O)C(O)C(O)C(O)=O RGHNJXZEOKUKBD-UHFFFAOYSA-N 0.000 description 1
- SHZGCJCMOBCMKK-UHFFFAOYSA-N D-mannomethylose Natural products CC1OC(O)C(O)C(O)C1O SHZGCJCMOBCMKK-UHFFFAOYSA-N 0.000 description 1
- WQZGKKKJIJFFOK-QTVWNMPRSA-N D-mannopyranose Chemical compound OC[C@H]1OC(O)[C@@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-QTVWNMPRSA-N 0.000 description 1
- QWIZNVHXZXRPDR-UHFFFAOYSA-N D-melezitose Natural products O1C(CO)C(O)C(O)C(O)C1OC1C(O)C(CO)OC1(CO)OC1OC(CO)C(O)C(O)C1O QWIZNVHXZXRPDR-UHFFFAOYSA-N 0.000 description 1
- SRBFZHDQGSBBOR-IOVATXLUSA-N D-xylopyranose Chemical compound O[C@@H]1COC(O)[C@H](O)[C@H]1O SRBFZHDQGSBBOR-IOVATXLUSA-N 0.000 description 1
- 241000196324 Embryophyta Species 0.000 description 1
- 229930091371 Fructose Natural products 0.000 description 1
- 239000005715 Fructose Substances 0.000 description 1
- RFSUNEUAIZKAJO-ARQDHWQXSA-N Fructose Chemical compound OC[C@H]1O[C@](O)(CO)[C@@H](O)[C@@H]1O RFSUNEUAIZKAJO-ARQDHWQXSA-N 0.000 description 1
- RGHNJXZEOKUKBD-SQOUGZDYSA-N Gluconic acid Natural products OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C(O)=O RGHNJXZEOKUKBD-SQOUGZDYSA-N 0.000 description 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
- 238000003794 Gram staining Methods 0.000 description 1
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 description 1
- 229930010555 Inosine Natural products 0.000 description 1
- UGQMRVRMYYASKQ-KQYNXXCUSA-N Inosine Chemical compound O[C@@H]1[C@H](O)[C@@H](CO)O[C@H]1N1C2=NC=NC(O)=C2N=C1 UGQMRVRMYYASKQ-KQYNXXCUSA-N 0.000 description 1
- 229920001202 Inulin Polymers 0.000 description 1
- LEVWYRKDKASIDU-IMJSIDKUSA-N L-cystine Chemical compound [O-]C(=O)[C@@H]([NH3+])CSSC[C@H]([NH3+])C([O-])=O LEVWYRKDKASIDU-IMJSIDKUSA-N 0.000 description 1
- 235000019393 L-cystine Nutrition 0.000 description 1
- 239000004158 L-cystine Substances 0.000 description 1
- SHZGCJCMOBCMKK-JFNONXLTSA-N L-rhamnopyranose Chemical compound C[C@@H]1OC(O)[C@H](O)[C@H](O)[C@H]1O SHZGCJCMOBCMKK-JFNONXLTSA-N 0.000 description 1
- PNNNRSAQSRJVSB-UHFFFAOYSA-N L-rhamnose Natural products CC(O)C(O)C(O)C(O)C=O PNNNRSAQSRJVSB-UHFFFAOYSA-N 0.000 description 1
- SRBFZHDQGSBBOR-OWMBCFKOSA-N L-ribopyranose Chemical compound O[C@H]1COC(O)[C@@H](O)[C@H]1O SRBFZHDQGSBBOR-OWMBCFKOSA-N 0.000 description 1
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 1
- GUBGYTABKSRVRQ-PICCSMPSSA-N Maltose Natural products O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@@H](CO)OC(O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-PICCSMPSSA-N 0.000 description 1
- 229930195725 Mannitol Natural products 0.000 description 1
- 240000007594 Oryza sativa Species 0.000 description 1
- 235000007164 Oryza sativa Nutrition 0.000 description 1
- MUPFEKGTMRGPLJ-RMMQSMQOSA-N Raffinose Natural products O(C[C@H]1[C@@H](O)[C@H](O)[C@@H](O)[C@@H](O[C@@]2(CO)[C@H](O)[C@@H](O)[C@@H](CO)O2)O1)[C@@H]1[C@H](O)[C@@H](O)[C@@H](O)[C@@H](CO)O1 MUPFEKGTMRGPLJ-RMMQSMQOSA-N 0.000 description 1
- PYMYPHUHKUWMLA-LMVFSUKVSA-N Ribose Natural products OC[C@@H](O)[C@@H](O)[C@@H](O)C=O PYMYPHUHKUWMLA-LMVFSUKVSA-N 0.000 description 1
- 240000004808 Saccharomyces cerevisiae Species 0.000 description 1
- NGFMICBWJRZIBI-JZRPKSSGSA-N Salicin Natural products O([C@H]1[C@H](O)[C@@H](O)[C@@H](O)[C@H](CO)O1)c1c(CO)cccc1 NGFMICBWJRZIBI-JZRPKSSGSA-N 0.000 description 1
- 229920002472 Starch Polymers 0.000 description 1
- BGNXCDMCOKJUMV-UHFFFAOYSA-N Tert-Butylhydroquinone Chemical compound CC(C)(C)C1=CC(O)=CC=C1O BGNXCDMCOKJUMV-UHFFFAOYSA-N 0.000 description 1
- HDTRYLNUVZCQOY-WSWWMNSNSA-N Trehalose Natural products O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@H](O)[C@@H](O)[C@@H](O)[C@@H](CO)O1 HDTRYLNUVZCQOY-WSWWMNSNSA-N 0.000 description 1
- 241000209140 Triticum Species 0.000 description 1
- 235000021307 Triticum Nutrition 0.000 description 1
- MUPFEKGTMRGPLJ-UHFFFAOYSA-N UNPD196149 Natural products OC1C(O)C(CO)OC1(CO)OC1C(O)C(O)C(O)C(COC2C(C(O)C(O)C(CO)O2)O)O1 MUPFEKGTMRGPLJ-UHFFFAOYSA-N 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 230000000996 additive effect Effects 0.000 description 1
- 210000001789 adipocyte Anatomy 0.000 description 1
- HDTRYLNUVZCQOY-LIZSDCNHSA-N alpha,alpha-trehalose Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 HDTRYLNUVZCQOY-LIZSDCNHSA-N 0.000 description 1
- HMFHBZSHGGEWLO-UHFFFAOYSA-N alpha-D-Furanose-Ribose Natural products OCC1OC(O)C(O)C1O HMFHBZSHGGEWLO-UHFFFAOYSA-N 0.000 description 1
- NGFMICBWJRZIBI-UHFFFAOYSA-N alpha-salicin Natural products OC1C(O)C(O)C(CO)OC1OC1=CC=CC=C1CO NGFMICBWJRZIBI-UHFFFAOYSA-N 0.000 description 1
- 229940089837 amygdalin Drugs 0.000 description 1
- YZLOSXFCSIDECK-UHFFFAOYSA-N amygdalin Natural products OCC1OC(OCC2OC(O)C(O)C(O)C2O)C(O)C(O)C1OC(C#N)c3ccccc3 YZLOSXFCSIDECK-UHFFFAOYSA-N 0.000 description 1
- PYMYPHUHKUWMLA-UHFFFAOYSA-N arabinose Natural products OCC(O)C(O)C(O)C=O PYMYPHUHKUWMLA-UHFFFAOYSA-N 0.000 description 1
- DLRVVLDZNNYCBX-ZZFZYMBESA-N beta-melibiose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@@H]1OC[C@@H]1[C@@H](O)[C@H](O)[C@@H](O)[C@H](O)O1 DLRVVLDZNNYCBX-ZZFZYMBESA-N 0.000 description 1
- 235000012970 cakes Nutrition 0.000 description 1
- 150000001720 carbohydrates Chemical class 0.000 description 1
- 235000014633 carbohydrates Nutrition 0.000 description 1
- 239000005018 casein Substances 0.000 description 1
- BECPQYXYKAMYBN-UHFFFAOYSA-N casein, tech. Chemical compound NCCCCC(C(O)=O)N=C(O)C(CC(O)=O)N=C(O)C(CCC(O)=N)N=C(O)C(CC(C)C)N=C(O)C(CCC(O)=O)N=C(O)C(CC(O)=O)N=C(O)C(CCC(O)=O)N=C(O)C(C(C)O)N=C(O)C(CCC(O)=N)N=C(O)C(CCC(O)=N)N=C(O)C(CCC(O)=N)N=C(O)C(CCC(O)=O)N=C(O)C(CCC(O)=O)N=C(O)C(COP(O)(O)=O)N=C(O)C(CCC(O)=N)N=C(O)C(N)CC1=CC=CC=C1 BECPQYXYKAMYBN-UHFFFAOYSA-N 0.000 description 1
- 235000021240 caseins Nutrition 0.000 description 1
- 210000004027 cell Anatomy 0.000 description 1
- 238000005119 centrifugation Methods 0.000 description 1
- 235000013339 cereals Nutrition 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 229960004874 choline bitartrate Drugs 0.000 description 1
- QWJSAWXRUVVRLH-UHFFFAOYSA-M choline bitartrate Chemical compound C[N+](C)(C)CCO.OC(=O)C(O)C(O)C([O-])=O QWJSAWXRUVVRLH-UHFFFAOYSA-M 0.000 description 1
- 235000009508 confectionery Nutrition 0.000 description 1
- 238000010411 cooking Methods 0.000 description 1
- 235000014510 cooky Nutrition 0.000 description 1
- 229960003067 cystine Drugs 0.000 description 1
- 125000002740 cytidyl group Chemical group 0.000 description 1
- 230000004069 differentiation Effects 0.000 description 1
- 239000002552 dosage form Substances 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 239000003814 drug Substances 0.000 description 1
- 239000003937 drug carrier Substances 0.000 description 1
- 239000003623 enhancer Substances 0.000 description 1
- 229940093496 esculin Drugs 0.000 description 1
- XHCADAYNFIFUHF-TVKJYDDYSA-N esculin Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1OC(C(=C1)O)=CC2=C1OC(=O)C=C2 XHCADAYNFIFUHF-TVKJYDDYSA-N 0.000 description 1
- AWRMZKLXZLNBBK-UHFFFAOYSA-N esculin Natural products OC1OC(COc2cc3C=CC(=O)Oc3cc2O)C(O)C(O)C1O AWRMZKLXZLNBBK-UHFFFAOYSA-N 0.000 description 1
- YGHHWSRCTPQFFC-UHFFFAOYSA-N eucalyptosin A Natural products OC1C(O)C(O)C(CO)OC1OC1C(OC(C#N)C=2C=CC=CC=2)OC(CO)C(O)C1O YGHHWSRCTPQFFC-UHFFFAOYSA-N 0.000 description 1
- 238000000855 fermentation Methods 0.000 description 1
- 230000004151 fermentation Effects 0.000 description 1
- 230000037406 food intake Effects 0.000 description 1
- 229930182830 galactose Natural products 0.000 description 1
- 239000000174 gluconic acid Substances 0.000 description 1
- 235000012208 gluconic acid Nutrition 0.000 description 1
- 239000008103 glucose Substances 0.000 description 1
- 230000004153 glucose metabolism Effects 0.000 description 1
- 239000002955 immunomodulating agent Substances 0.000 description 1
- 229940121354 immunomodulator Drugs 0.000 description 1
- 230000002584 immunomodulator Effects 0.000 description 1
- 239000004615 ingredient Substances 0.000 description 1
- 229910052500 inorganic mineral Inorganic materials 0.000 description 1
- 229960003786 inosine Drugs 0.000 description 1
- 230000008944 intestinal immunity Effects 0.000 description 1
- 229940029339 inulin Drugs 0.000 description 1
- JYJIGFIDKWBXDU-MNNPPOADSA-N inulin Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)OC[C@]1(OC[C@]2(OC[C@]3(OC[C@]4(OC[C@]5(OC[C@]6(OC[C@]7(OC[C@]8(OC[C@]9(OC[C@]%10(OC[C@]%11(OC[C@]%12(OC[C@]%13(OC[C@]%14(OC[C@]%15(OC[C@]%16(OC[C@]%17(OC[C@]%18(OC[C@]%19(OC[C@]%20(OC[C@]%21(OC[C@]%22(OC[C@]%23(OC[C@]%24(OC[C@]%25(OC[C@]%26(OC[C@]%27(OC[C@]%28(OC[C@]%29(OC[C@]%30(OC[C@]%31(OC[C@]%32(OC[C@]%33(OC[C@]%34(OC[C@]%35(OC[C@]%36(O[C@@H]%37[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O%37)O)[C@H]([C@H](O)[C@@H](CO)O%36)O)[C@H]([C@H](O)[C@@H](CO)O%35)O)[C@H]([C@H](O)[C@@H](CO)O%34)O)[C@H]([C@H](O)[C@@H](CO)O%33)O)[C@H]([C@H](O)[C@@H](CO)O%32)O)[C@H]([C@H](O)[C@@H](CO)O%31)O)[C@H]([C@H](O)[C@@H](CO)O%30)O)[C@H]([C@H](O)[C@@H](CO)O%29)O)[C@H]([C@H](O)[C@@H](CO)O%28)O)[C@H]([C@H](O)[C@@H](CO)O%27)O)[C@H]([C@H](O)[C@@H](CO)O%26)O)[C@H]([C@H](O)[C@@H](CO)O%25)O)[C@H]([C@H](O)[C@@H](CO)O%24)O)[C@H]([C@H](O)[C@@H](CO)O%23)O)[C@H]([C@H](O)[C@@H](CO)O%22)O)[C@H]([C@H](O)[C@@H](CO)O%21)O)[C@H]([C@H](O)[C@@H](CO)O%20)O)[C@H]([C@H](O)[C@@H](CO)O%19)O)[C@H]([C@H](O)[C@@H](CO)O%18)O)[C@H]([C@H](O)[C@@H](CO)O%17)O)[C@H]([C@H](O)[C@@H](CO)O%16)O)[C@H]([C@H](O)[C@@H](CO)O%15)O)[C@H]([C@H](O)[C@@H](CO)O%14)O)[C@H]([C@H](O)[C@@H](CO)O%13)O)[C@H]([C@H](O)[C@@H](CO)O%12)O)[C@H]([C@H](O)[C@@H](CO)O%11)O)[C@H]([C@H](O)[C@@H](CO)O%10)O)[C@H]([C@H](O)[C@@H](CO)O9)O)[C@H]([C@H](O)[C@@H](CO)O8)O)[C@H]([C@H](O)[C@@H](CO)O7)O)[C@H]([C@H](O)[C@@H](CO)O6)O)[C@H]([C@H](O)[C@@H](CO)O5)O)[C@H]([C@H](O)[C@@H](CO)O4)O)[C@H]([C@H](O)[C@@H](CO)O3)O)[C@H]([C@H](O)[C@@H](CO)O2)O)[C@@H](O)[C@H](O)[C@@H](CO)O1 JYJIGFIDKWBXDU-MNNPPOADSA-N 0.000 description 1
- 239000008101 lactose Substances 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 239000000594 mannitol Substances 0.000 description 1
- 235000010355 mannitol Nutrition 0.000 description 1
- QWIZNVHXZXRPDR-WSCXOGSTSA-N melezitose Chemical compound O([C@@]1(O[C@@H]([C@H]([C@@H]1O[C@@H]1[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O1)O)O)CO)CO)[C@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O QWIZNVHXZXRPDR-WSCXOGSTSA-N 0.000 description 1
- HOVAGTYPODGVJG-ZFYZTMLRSA-N methyl alpha-D-glucopyranoside Chemical compound CO[C@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O HOVAGTYPODGVJG-ZFYZTMLRSA-N 0.000 description 1
- 239000011707 mineral Substances 0.000 description 1
- 230000004899 motility Effects 0.000 description 1
- 235000012149 noodles Nutrition 0.000 description 1
- 230000003287 optical effect Effects 0.000 description 1
- 239000008188 pellet Substances 0.000 description 1
- 239000000546 pharmaceutical excipient Substances 0.000 description 1
- 238000002360 preparation method Methods 0.000 description 1
- MUPFEKGTMRGPLJ-ZQSKZDJDSA-N raffinose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO[C@@H]2[C@@H]([C@@H](O)[C@@H](O)[C@@H](CO)O2)O)O1 MUPFEKGTMRGPLJ-ZQSKZDJDSA-N 0.000 description 1
- 235000009566 rice Nutrition 0.000 description 1
- NGFMICBWJRZIBI-UJPOAAIJSA-N salicin Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1OC1=CC=CC=C1CO NGFMICBWJRZIBI-UJPOAAIJSA-N 0.000 description 1
- 229940120668 salicin Drugs 0.000 description 1
- 239000000600 sorbitol Substances 0.000 description 1
- 235000012424 soybean oil Nutrition 0.000 description 1
- 239000003549 soybean oil Substances 0.000 description 1
- 239000008107 starch Substances 0.000 description 1
- 235000019698 starch Nutrition 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 239000004250 tert-Butylhydroquinone Substances 0.000 description 1
- 235000019281 tert-butylhydroquinone Nutrition 0.000 description 1
- 239000011782 vitamin Substances 0.000 description 1
- 229940088594 vitamin Drugs 0.000 description 1
- 229930003231 vitamin Natural products 0.000 description 1
- 235000013343 vitamin Nutrition 0.000 description 1
- 150000003722 vitamin derivatives Chemical class 0.000 description 1
- 235000013618 yogurt Nutrition 0.000 description 1
Images
Landscapes
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Medicinal Preparation (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Description
本発明は、インフルエンザワクチンのアジュバントに関する。アジュバントとは、薬剤の効果を増強する添加剤（助剤、免疫強化剤、免疫調整剤などとも呼ばれている）のことであり、本発明のアジュバントは、インフルエンザウイルスＰＲ８株などから調製されたインフルエンザワクチンの効果を増強する作用を有するものである。 The present invention relates to an influenza vaccine adjuvant. An adjuvant is an additive (also called an adjuvant, immune enhancer, immunomodulator, etc.) that enhances the effect of the drug, and the adjuvant of the present invention was prepared from influenza virus PR8 strain or the like It has the effect | action which strengthens the effect of an influenza vaccine.
インフルエンザウイルスＰＲ８株などから調製されたインフルエンザワクチンのアジュバントとして、種々の物質が知られている。例えば、コレラ毒素、ポリリボ（イノシン：シチジル）酸、キチン微粉末、貝殻微粉末などが、インフルエンザワクチンのアジュバントとして検討されている（非特許文献１〜５参照）。これらの他、多数の非特許文献に見られるように、インフルエンザワクチンのアジュバントとしての効能を試験する際には、インフルエンザウイルスＰＲ８株を代表株として用いられることが知られている。
Various substances are known as adjuvants for influenza vaccines prepared from influenza virus strain PR8 and the like. For example, cholera toxin, polyribo (inosine: cytidyl) acid, chitin fine powder, shell fine powder and the like have been studied as adjuvants for influenza vaccines (see Non-Patent
本発明の目的は、インフルエンザウイルスＰＲ８株などから調製されたインフルエンザワクチンの効果を増強する作用を有する、安全な天然由来の乳酸菌（植物性乳酸菌）を有効成分として含有するインフルエンザワクチンのアジュバントを提供することである。 An object of the present invention is to provide an adjuvant for influenza vaccine containing as an active ingredient a safe naturally-derived lactic acid bacterium (plant lactic acid bacterium) having an action of enhancing the effect of an influenza vaccine prepared from influenza virus PR8 strain or the like. That is.
本発明者らは、上記目的を達成すべく種々検討した結果、パン生地から分離したラクトバチルス・プランタラム（Ｌａｃｔｏｂａｃｉｌｌｕｓ ｐｌａｎｔａｒｕｍ）に属する特定の乳酸菌を、インフルエンザウイルスＰＲ８株などから調製されたインフルエンザワクチンの投与前に継続的に摂取しておくことにより、インフルエンザワクチンの効果が増強することを見出し、本発明を完成するに至った。
すなわち、本発明は、ラクトバチルス・プランタラムＡＹＡ株を有効成分として含有し、インフルエンザワクチンの経口投与前に摂取される、インフルエンザワクチンのアジュバントを提供するものである。
ラクトバチルス・プランタラムＡＹＡ株は、パン生地から分離された株であり、オリエンタル酵母工業株式会社（東京都板橋区小豆沢３丁目６番１０号）により、２００６年１１月２９日付で独立行政法人産業技術総合研究所特許生物寄託センター（茨城県つくば市東１丁目１番地１中央第６）に、受託番号ＦＥＲＭ Ｐ−２１１０６として寄託されている。
なお、ラクトバチルス・プランタラムＡＹＡ株は、特開２００８−１７９５９５号公報に記載された乳酸菌であり、これを用いて麦を乳酸菌発酵させた産物を有効成分とする脂肪細胞分化促進剤も同公開公報に記載されている。さらに、ラクトバチルス・プランタラムＡＹＡ株は、特願２００７−３９０１９号に係る腸管免疫力増強剤の有効成分としても提案されているが、ラクトバチルス・プランタラムＡＹＡ株単体がインフルエンザワクチンのアジュバントとしての効能を持つことは、本発明者らによって初めて見い出されたことである。
As a result of various studies to achieve the above object, the present inventors administered a specific lactic acid bacterium belonging to Lactobacillus plantarum isolated from bread dough as an influenza vaccine prepared from influenza virus PR8 strain or the like. It has been found that the effect of influenza vaccine is enhanced by continuously ingesting before, and the present invention has been completed.
That is, the present invention provides an influenza vaccine adjuvant that contains the Lactobacillus plantarum AYA strain as an active ingredient and is taken before oral administration of the influenza vaccine.
Lactobacillus plantarum AYA strain is a strain isolated from bread dough, and is produced by Oriental Yeast Industry Co., Ltd. (3-6-10 Shodozawa, Itabashi-ku, Tokyo) as of November 29, 2006. Deposited at the Research Institute Patent Biological Deposit Center (1st, 1st East, 1st Street, Tsukuba City, Ibaraki Prefecture, 6th) as deposit number FERM P-21106.
The Lactobacillus plantarum AYA strain is a lactic acid bacterium described in Japanese Patent Application Laid-Open No. 2008-179595, and an adipocyte differentiation promoter containing a product obtained by fermenting wheat using lactic acid bacteria as an active ingredient is also disclosed. It is described in the publication. Furthermore, the Lactobacillus plantarum AYA strain has also been proposed as an active ingredient of the intestinal immunity enhancing agent according to Japanese Patent Application No. 2007-39019, but the Lactobacillus plantarum AYA strain alone is used as an adjuvant for influenza vaccines. It has been found for the first time by the present inventors to have efficacy.
本発明のインフルエンザワクチンのアジュバントは、インフルエンザウイルスＰＲ８株などから調製されたインフルエンザワクチンの投与前に継続的に摂取しておくことにより、インフルエンザワクチンの効果を増強する作用を有する。また、本発明のインフルエンザワクチンのアジュバントは、有効成分であるラクトバチルス・プランタラムＡＹＡ株が食経験のある天然食品素材から分離した乳酸菌であるので、安全性にも優れている。 The adjuvant of the influenza vaccine of this invention has the effect | action which strengthens the effect of an influenza vaccine by ingesting continuously before administration of the influenza vaccine prepared from influenza virus PR8 strain | stump | stock. Moreover, since the Lactobacillus plantarum AYA strain which is an active ingredient is an lactic acid bacterium isolated from a natural food material with experience, the adjuvant of the influenza vaccine of the present invention is excellent in safety.
乳酸菌ラクトバチルス・プランタラムＡＹＡ株の菌学的性質を下記に示す。
ＭＲＳ液体培地（ＤＩＦＣＯ社）を用いて、３０℃、１８時間培養したときの菌の形態（１）菌の形態 桿菌
（２）グラム染色 陽性
（３）運動性 なし
（４）胞子 なし
（５）カタラーゼ なし
（６）通性嫌気性
（７）ブドウ糖の代謝 ５０％以上乳酸に転換する
（８）生育温度範囲 １５℃、３０℃および３５℃では生育を認めるが、４５℃では生育を認めない
（９）乳酸発酵 ホモ型
（１０）乳酸の旋光性 ＤＬ
（１１）炭水化物の発酵性 グリセロールは陽性、Ｄ−アラビノースは陰性、Ｌ−アラビノースは陽性、リボースは陽性、Ｄ−キシロースは陰性、ガラクトースは陽性、グルコースは陽性、フルクトースは陽性、マンノースは陽性、ラムノースは陽性、マンニトールは陽性、ソルビトールは陽性、αメチルＤグルコシドは陰性、アミグダリンは陽性、エスクリンは陽性、サリシンは陽性、セロビオースは陽性、マルトースは陽性、ラクトースは陽性、メリビオースは陽性、シュクロースは陽性、トレハロースは陽性、イヌリンは陰性、メレジトースは陽性、ラフィノースは陽性、スターチは陰性、グルコン酸は陽性。
The mycological properties of the lactic acid bacterium Lactobacillus plantarum AYA are shown below.
Bacteria morphology when cultured for 18 hours at 30 ° C. using MRS liquid medium (DIFCO) (1) Bacteria morphology Bacilli (2) Gram staining Positive (3) Motility None (4) Spore None (5) Catalase None (6) Facultative anaerobic (7) Glucose metabolism Convert to 50% or more lactic acid (8) Growth temperature range Growth is observed at 15 ° C, 30 ° C and 35 ° C, but growth is not observed at 45 ° C ( 9) Lactic acid fermentation Homo type (10) Optical rotation of lactic acid DL
(11) Carbohydrate fermentability Glycerol is positive, D-arabinose is negative, L-arabinose is positive, ribose is positive, D-xylose is negative, galactose is positive, glucose is positive, fructose is positive, mannose is positive, rhamnose Is positive, mannitol is positive, sorbitol is positive, α-methyl D-glucoside is negative, amygdalin is positive, esculin is positive, salicin is positive, cellobiose is positive, maltose is positive, lactose is positive, melibiose is positive, sucrose is positive Positive for trehalose, negative for inulin, positive for melezitose, positive for raffinose, negative for starch, positive for gluconic acid.
乳酸菌ラクトバチルス・プランタラムＡＹＡ株は、食経験が豊富な素材（パン生地）から分離したものであるため、安全に利用することができる。 Since the lactic acid bacterium Lactobacillus plantarum AYA strain is separated from a material (bread dough) rich in food experience, it can be used safely.
乳酸菌ラクトバチルス・プランタラムＡＹＡ株は、そのままあるいは必要に応じて薬学的に許容される種々の担体、賦形剤、その他の添加剤、その他の成分を適宜配合して製剤化することによって、インフルエンザワクチンのアジュバントとすることができる。 The lactic acid bacterium Lactobacillus plantarum AYA strain can be used to prepare various pharmaceutically acceptable carriers, excipients, other additives, and other ingredients as they are or as necessary. It can be an adjuvant for a vaccine.
また、本発明のインフルエンザワクチンのアジュバントは、食品の形態、例えば、パン、菓子、クッキー、ケーキ、麺、粥、雑炊、シリアルバー、ドリンク、ヨーグルトなどの形態で提供することもできる。 Moreover, the adjuvant of the influenza vaccine of this invention can also be provided with the form of foodstuffs, for example, forms, such as bread, confectionery, a cookie, a cake, noodles, rice cakes, miscellaneous cooking, a cereal bar, a drink, and a yoghurt.
本発明のインフルエンザワクチンのアジュバント中の乳酸菌ラクトバチルス・プランタラムＡＹＡ株の含有量は、制限されるものではなく、使用形態、アジュバントの剤形や投与又は摂取する者の年齢性別などによって適宜変化させることができる。本発明のアジュバントを経口投与又は摂取させる場合には、１人１日当たりのラクトバチルス・プランタラムＡＹＡ株の投与量又は摂取量が１ｍｇ〜２０ｇとなるように、ラクトバチルス・プランタラムＡＹＡ株を本発明のアジュバント中に含有させることが好ましい。 The content of the lactic acid bacteria Lactobacillus plantarum AYA strain in the adjuvant of the influenza vaccine of the present invention is not limited, and is appropriately changed depending on the use form, the dosage form of the adjuvant, the age sex of the person who administers or ingests, etc. be able to. When the adjuvant of the present invention is orally administered or ingested, the Lactobacillus plantarum AYA strain is selected so that the dose or ingestion amount of Lactobacillus plantarum AYA per person per day is 1 mg to 20 g. It is preferably contained in the adjuvant of the invention.
本発明のインフルエンザワクチンのアジュバントは、インフルエンザウイルスＰＲ８株などから調製されたインフルエンザワクチンの投与前に継続的に摂取しておくことが好ましく、インフルエンザワクチンの投与の少なくとも７日前から継続的に摂取しておくことがより好ましい。 The adjuvant of the influenza vaccine of the present invention is preferably taken continuously before the administration of an influenza vaccine prepared from influenza virus PR8 strain or the like, and is taken continuously from at least 7 days before the administration of the influenza vaccine. More preferably.
次に本発明をさらに具体的に説明するために実施例を挙げるが、本発明は、以下の実施例に制限されるものではない。 EXAMPLES Next, examples are given to describe the present invention more specifically, but the present invention is not limited to the following examples.
実施例１
（乳酸菌試料の調製）
ラクトバチルス・プランタラムＡＹＡ株を、１０μｇ／ｍｌシクロヘキシミドを含むＭＲＳ（ｄｅ Ｍａｎ−Ｒｏｇｏｓａ−Ｓｈａｒｐｅ）培地を用いて３７℃で４８時間培養した。その後、遠心分離によって集菌し、滅菌水で３回洗浄した後、滅菌水に懸濁し、１２１℃で３０分間オートクレーブ処理し、これを凍結乾燥して乳酸菌試料を得た。
Example 1
(Preparation of lactic acid bacteria sample)
The Lactobacillus plantarum AYA strain was cultured at 37 ° C. for 48 hours using MRS (de Man-Rogosa-Sharpe) medium containing 10 μg / ml cycloheximide. Thereafter, the cells were collected by centrifugation, washed three times with sterilized water, suspended in sterilized water, autoclaved at 121 ° C. for 30 minutes, and freeze-dried to obtain lactic acid bacteria samples.
ＢＡＬＢ／ｃマウス（各群４匹）に餌を７２日間投与した後、インフルエンザウイルスＰＲ８株をフォルムアミドで不活化したワクチン（１５０μｇ／２００μｌ ０．２Ｍ ＮａＨＣＯ3）を経口投与した。餌として、対照群にはＡＩＮ−９３Ｇ（カゼイン２０質量％、Ｌ-シスチン０．３質量％、コーンスターチ３９．７４８６質量％、α化コーンスターチ１３．２質量％、シュークロース１０質量％、大豆油７質量％、セルロースパウダー５質量％、ＡＩＮ−９３Ｇミネラル混合３．５質量％、ＡＩＮ−９３Ｇビタミン混合１質量％、重酒石酸コリン０．２５質量％、第三ブチルヒドロキノン０．００１４質量％）をペレット化し、γ線滅菌したものを投与し、乳酸菌試料投与群にはＡＩＮ−９３Ｇに上記乳酸菌試料を５質量％含有させたものをペレット化し、γ線滅菌したものを投与した。ワクチン投与後５９日目にインフルエンザウイルスＰＲ８株２０ＬＤ５０（８４０００ＴＣＩＤ５０／２０μｌ）をＢＡＬＢ／ｃマウスに経鼻感染させ、その３日目に解剖し、小腸を切除し、大腸側（回腸側）の洗浄液中のＰＲ８特異的ＩｇＡ濃度をＥＬＩＳＡ法により測定した。
その結果、図１に示すように、乳酸菌試料投与群の回腸側のＰＲ８特異的ＩｇＡ濃度は、対照群に比べて有意（危険率５％）に上昇していた。
BALB / c mice (4 mice in each group) were fed with food for 72 days, and were orally administered with a vaccine in which the influenza virus PR8 strain was inactivated with formamide (150 μg / 200 μl 0.2 M NaHCO 3 ). As a bait, the control group contained AIN-93G (casein 20 mass%, L-cystine 0.3 mass%, corn starch 39.7486 mass%, pregelatinized corn starch 13.2 mass%,
As a result, as shown in FIG. 1, the PR8-specific IgA concentration on the ileum side in the lactic acid bacteria sample administration group was significantly increased (risk rate 5%) as compared with the control group.
実施例２
ＢＡＬＢ／ｃマウス（各群６匹）に餌を４２日間投与した後、インフルエンザウイルスＰＲ８株をフォルムアミドで不活化したワクチン（１５０μｇ／２００μｌ ０．２Ｍ ＮａＨＣＯ3）を経口投与した。餌として、対照群にはＡＩＮ９７をペレット化し、γ線滅菌したものを投与し、乳酸菌試料投与群にはＡＩＮ９７に上記乳酸菌試料を５質量％含有させたものをペレット化し、γ線滅菌したものを投与した。ワクチン投与後１４日目にインフルエンザウイルスＰＲ８株２０ＬＤ５０（８４０００ＴＣＩＤ５０／２０μｌ）をＢＡＬＢ／ｃマウスに経鼻感染させ、その３日目に解剖し、小腸を切除し、大腸側（回腸側）の洗浄液中のＰＲ８特異的ＩｇＡ濃度をＥＬＩＳＡ法により測定した。
その結果、図２に示すように、乳酸菌試料投与群の回腸側のＰＲ８特異的ＩｇＡ濃度は、対照群に比べて有意に上昇していた。
Example 2
BALB / c mice (6 mice in each group) were fed with food for 42 days and then orally administered with a vaccine in which the influenza virus PR8 strain was inactivated with formamide (150 μg / 200 μl 0.2 M NaHCO 3 ). As the bait, the control group was pelleted with AIN97 and sterilized with γ-rays, and the lactic acid bacteria sample-administered group was pelleted with AIN97 containing 5% by mass of the lactic acid bacteria sample and sterilized with γ-rays. Administered. On day 14 after vaccine administration, influenza virus PR8 strain 20LD50 (84000TCID50 / 20 μl) was infected nasally in BALB / c mice, dissected on day 3, excised the small intestine, and in the large intestine side (ileal side) lavage fluid The PR8-specific IgA concentration was measured by ELISA.
As a result, as shown in FIG. 2, the PR8-specific IgA concentration on the ileum side in the lactic acid bacteria sample administration group was significantly higher than that in the control group.
Claims (1)
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2008210484A JP5426850B2 (en) | 2008-08-19 | 2008-08-19 | Influenza vaccine adjuvant |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2008210484A JP5426850B2 (en) | 2008-08-19 | 2008-08-19 | Influenza vaccine adjuvant |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2010047485A JP2010047485A (en) | 2010-03-04 |
| JP5426850B2 true JP5426850B2 (en) | 2014-02-26 |
Family
ID=42064898
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2008210484A Active JP5426850B2 (en) | 2008-08-19 | 2008-08-19 | Influenza vaccine adjuvant |
Country Status (1)
| Country | Link |
|---|---|
| JP (1) | JP5426850B2 (en) |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP6713751B2 (en) | 2015-10-26 | 2020-06-24 | キリンホールディングス株式会社 | Method for enhancing specific cytotoxic T cell (CTL) and antibody production against antigen |
Family Cites Families (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ITMI20042189A1 (en) * | 2004-11-16 | 2005-02-16 | Anidral Srl | COMPOSITION BASED ON PROBIOTIC BACTERIA AND ITS USE IN THE PREVENTION OF E-OR IN THE TREATMENT OF PATHOLOGIES AND-OR RESPIRATORY INFECTIONS AND IN THE IMPROVEMENT OF INTESTINAL FUNCTIONALITY |
-
2008
- 2008-08-19 JP JP2008210484A patent/JP5426850B2/en active Active
Also Published As
| Publication number | Publication date |
|---|---|
| JP2010047485A (en) | 2010-03-04 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP4455333B2 (en) | Probiotic bacteria: Lactobacillus fermentum | |
| JP6420535B2 (en) | Novel lactic acid bacteria having IgA production promoting action and use thereof | |
| US20110038837A1 (en) | Composition for improving intestinal microflora | |
| CA3010577A1 (en) | A composition comprising a lactic acid bacteria for preventing and treating vaginosis and the use thereof | |
| EP3808357B1 (en) | Composition comprising megamonas funiformis and anaerofustis stercorihominis and use thereof | |
| JP2006522766A (en) | Symbiotic combination | |
| JP7179343B2 (en) | Novel lactic acid strain and immunostimulant containing the same | |
| JP5144085B2 (en) | Intestinal immunity enhancing agent containing lactic acid bacteria having IgA antibody production improving action | |
| CN114146101A (en) | Application of bifidobacterium animalis subsp lactis BLA80 in preparing medicine or food for regulating intestinal motility | |
| CN118843685A (en) | Novel probiotics and uses thereof | |
| KR20180118363A (en) | Lactobacillus plantarum having anti-inflammation and metabolic disease improvement effect and uses thereof | |
| US20130309212A1 (en) | Lactobacillus salivarius and method for preparing metabolite thereof, composition of lactobacillus salivarius and metabolite thereof and use of the composition | |
| CN113286872A (en) | Novel bacterium genus Dysosmobacter of gastrointestinal tract microbiota and use thereof | |
| JP6557605B2 (en) | Intestinal barrier function enhancer containing lactic acid bacteria | |
| Nagpal et al. | Probiotics, prebiotics and synbiotics: An introduction | |
| JP5426850B2 (en) | Influenza vaccine adjuvant | |
| EP2123291B1 (en) | Use of Lactobacillus amylovorus for treating periodontal diseases by stimulating IgA production | |
| JP5967527B2 (en) | Appetite increase and weight gain inhibitor | |
| CN112312920A (en) | Non-viable bifidobacterium bifidum and uses thereof | |
| WO2023108055A1 (en) | Bacillus clausii strain, compositions thereof, and methods of use | |
| JP2024544211A (en) | BACILLUS COAGULANS STRAINS, COMPOSITIONS THEREOF AND METHODS OF USE | |
| JP6671950B2 (en) | Functional gastrointestinal amelioration agent | |
| CN119177198B (en) | A herba Pentaenix for regulating and improving diarrhea, constipation and irritable bowel syndrome | |
| JP2013053089A (en) | Prophylactic/therapeutic agent for viral disease |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20110120 |
|
| A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20121225 |
|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20130212 |
|
| A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20130326 |
|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20130522 |
|
| TRDD | Decision of grant or rejection written | ||
| A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 Effective date: 20131119 |
|
| A61 | First payment of annual fees (during grant procedure) |
Free format text: JAPANESE INTERMEDIATE CODE: A61 Effective date: 20131129 |
|
| R150 | Certificate of patent or registration of utility model |
Free format text: JAPANESE INTERMEDIATE CODE: R150 Ref document number: 5426850 Country of ref document: JP Free format text: JAPANESE INTERMEDIATE CODE: R150 |
|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |